Business Wire

Nonprofit Funding Platform Heroe5 Launches The Good Society, Embracing Web3 Approach to the Sustainable Financial Benefit for Charities

Share

Nonprofit funding platform Heroe5™ announced today the creation of The Good Society™ to address the growing need for sustainable funding platforms for charitable organizations. The Good Society becomes the first project focused on Web3 solutions to raise awareness and support global causes working to positively impact our communities.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220728005376/en/

“The Good Society is a vital next step in the evolution of the fundraising industry: a Web3 platform to create art impact experiences,” said Sebastien Heimann, founding member and CEO of Heroe5 and The Good Society. “As the world moves to Web3, charities need more fundraising tools to stay ahead of the curve and embrace new ways to engage potential donors. The Good Society will provide those innovations, allowing them to raise critical funding and awareness for vital causes while feeding the public’s growing interest in digital collectables.”

With each drop 1800 digital collectibles designed by acclaimed artists will be released each month supporting a broad range of nonprofits working to improve the environment, wildlife, human rights, and our collective health and wellbeing. A percentage of these art impact experiences will grant token carriers access to unique events in perpetuity.

Artist Nate Mohler created “Out of Sight | Out of Mind” for The Good Society’s first program, which benefits Lonely Whale, No More Plastic, and Oceanic Global. The digital collectables, scaled to 3840 x 3840 pixels, 26 seconds in length and layered with “white sound,” emphasize the risk to fragile ocean ecosystems from the human-caused plastic pollution in urban environments and highlight how much there is left to learn. Three of the many cities featured in “Out of Sight | Out of Mind” include London, Los Angeles, and Paris.

“No matter where you live, the oceans provide the oxygen you breathe, nurture the food you eat, and regulate the temperature of the air. Without a healthy ocean we’d have a very different experience on land,” said Mohler. “This series is not of the oceans but of major cities, which emit 60% of all carbon emissions and make up less than 1% of the Earth’s surface. Similar to my ongoing series ‘Painted Cities’ there are three unique styles intended to bring a more ephemeral and dreamlike memory of the city.”

One of every 15 of the digital collectibles will also provide owners access to experiences that are provided by the benefiting organizations and artists for each drop. Some of the experiences tied to this premier release include:

  • Two front row seats at Paris Fashion Week
  • Two passes to Oceanic Global’s annual gathering for ocean conservation
  • An annual artist critique call with Nate Mohler
  • Invitations to Lonely Whale's annual leadership virtual town hall which discuss its programs and preview its impact report

Digital collectors will easily be able to purchase the artwork with a credit card or Tez, cryptocurrency of the Tezos blockchain, when they are minted on August 12 at 2pm ET. Once sold out, more than $1M (US) in new funding will be available to the benefiting organizations and, as the digital collectables are resold, the organizations will receive residual payments from each transaction.

Quotes from Benefiting Organizations

“Lonely Whale’s goal is simple - to keep plastic out of the ocean. We want to thank each person who buys one of Nate Mohler’s striking NFTs through The Good Society, which will support the creative development and market adoption of alternatives to thin-film plastic and directly address the nearly 180 billion polybags used every year by the fashion industry.” Harry Bernstein, Chief Creative Officer, Lonely Whale

“Plastic pollution has become one of the biggest environmental scourges of our time. Microplastics are everywhere: in the deep ocean, in Antarctic ice, even falling rain over mountains and cities. Plastic pollution not only pollutes our planet; it pollutes our blood. We must act and the time is now. We are grateful to The Good Society for entrusting No More Plastic Foundation with this generous funding. With it, we will continue our work to end the cycle of plastics and microplastics flowing into our ocean.” Rosalie Mann, Founder & President, No More Plastic

“We live on a blue planet. The ocean covers 70% of the surface of the earth and produces every other breath we take. Our well-being is intrinsically tied to the ocean. Thanks to The Good Society and their innovative fundraising platform and model – and to artiste extraordinaire Nate Mohler – Oceanic Global will be able to keep empowering individuals, communities, and industries to create positive change for a thriving ocean.” – Lea d'Auriol, Founder & Executive Director, Oceanic Global

About The Good Society
The Good Society harnesses the power of non fungible tokens to fund global initiatives. Designed by acclaimed digital artists, every month a new NFT will drop that raises awareness and secures funding for nonprofits working to improve the environment, human rights, and our collective health and wellbeing. Led by Sebastien Heimann, the Co-founder & CEO of fundraising platform Heroe5, The Good Society leverages the uniqueness of Web3 to deliver a powerful and recurring source of funding. For more information visit thegoodsociety.org.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Press
Famous Last Words PR
Carolyn Zweifel: carolyn@flwpr.com
Fred Shank: fred@flwpr.com
Jen Peros: jen@flwpr.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 11:00:00 EET | Press release

Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in

Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 11:00:00 EET | Press release

Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration

Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 11:00:00 EET | Press release

Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo

Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 10:00:00 EET | Press release

Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of

Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 09:44:00 EET | Press release

Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye